| May 16, 2013 |
Bio-Path Holdings Reports First Quarter 2013 Operational and Financial Results |
| Apr 2, 2013 |
Bio-Path Holdings Reports Fiscal Year 2012 Operational and Financial Results |
| Mar 7, 2013 |
Bio-Path Holdings Begins Enrollment in Fifth Cohort of Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemias |
| Jan 3, 2013 |
Bio-Path Holdings to Present at Biotech Showcase 2013 Conference in San Francisco, California on Tuesday, January 8, 2013 at 11:00 am Pacific Time |
| Dec 6, 2012 |
Bio-Path Holdings to Expand Development of Liposomal Grb-2 into two additional indications: Triple Negative and Inflammatory Breast Cancers |
| Nov 16, 2012 |
Bio-Path Holdings Reports Third Quarter 2012 Operational and Financial Results |
| Nov 14, 2012 |
Bio-Path Holdings Successfully Completes Fourth Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia |
| Oct 4, 2012 |
Bio-Path Holdings Adds New Board Member |
| Oct 3, 2012 |
Bio-Path Holdings to Present at the 11th Annual Bio Investor Forum Conference in San Francisco on Wednesday Oct 10, 2012 at 11:30 am Pacific Time (2:30 pm Eastern Time)
Webcast link here. |
| Sep 4, 2012 |
Bio-Path Holdings to Present at the Rodman & Renshaw Annual Global Investment Conference |
| Aug 24, 2012 |
Bio-Path Holdings to Present at the 2012 Southern California Investor Conference
Webcast Link Here |
| Aug 16, 2012 |
Bio-Path Holdings Reports Second Quarter 2012 Operational and Financial Results |
| Jul 25, 2012 |
Bio-Path Holdings Begins Enrollment in Fourth Cohort of Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemias |
| May 29, 2012 |
Bio-Path Holdings Successfully Completes Third Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia |
| May 17, 2012 |
Bio-Path Holdings Reports First Quarter 2012 Operational and Financial Results - Quarter Highlighted by Progress with Lead Product Candidate, Liposomal Grb-2 |
| Apr 3, 2012 |
Bio-Path Holdings Reports Fiscal Year 2011 Operational and Financial Results |
| Mar 29, 2012 |
Bio-Path Holdings Engages PondelWilkinson for Retailer Investor Relations Program |
| Feb 7, 2012 |
Bio-Path Holdings Successfully Completes Second Cohort in
Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia |
| Jan 4, 2012 |
Bio-Path Holdings to Present at Biotech Showcase 2012 Conference |
| Dec 13, 2011 |
Bio-Path Holdings' Initial Phase I Data in Leukemia Clinical Trial Demonstrates that Its Neutral Lipid Delivery Technology Antisense Drug BP-101-100-1.01 (Liposomal Grb-2) Is Well Tolerated with Activity Seen at Low-Starting Dose |
| Nov 15, 2011 |
Press Release Form 8-K - 3rd Quarter Financial Results |
| Oct 24, 2011 |
Proxy Statement fothereer 2011
|
| Oct 19, 2011 |
Bio-Path Holdings to Present at the 10th Annual BIO Investors Forum Conference in San Francisco on Wednesday, October 26, 2011. Link to Conference at 3:00pm Pacific Time |
| Oct 4, 2011 |
Initial Data from Bio-Path Holdings' Phase I Clinical Trial Accepted for Presentation at American Society ofHematology Annual Meeting |
| Sep 6, 2011 |
Bio-Path Holdings to Present at the Rodman & RenshawAnnual Global Investment Conference
Link to Conference on September 13, 2011 at 4:55 pm Eastern Time |
| Aug 11, 2011 |
First Cohort Successfully Completed in Bio-Path Holding’s Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia |
| Jul 27, 2011 |
Bio-Path recently featured in Genomeweb/Gene Silencing News |
| May 17, 2011 |
Bio-Path Holdings Reports First Quarter 2011 Financial Results |
| Apr 28, 2011 |
Bio-Path Holdings Appoints Dr. Ana M. Tari Director, Preclinical Operations and Research |
| Apl 4, 2011 |
Zack's Small-Cap Research Release |
| Mar 31, 2011 |
Bio-Path Holdings Reports Fiscal Year 2010 Operation and Financial Results |
| Feb 23, 2011 |
CEOCFO Interviews Peter H. Nielsen, CEO |
| Feb 23, 2011 |
Zack's Small-Cap Research Release |
| Nov 15, 2010 |
Bio-Path Holdings Reports Third Quarter 2010 Financial Results |
| Nov 3, 2010 |
Bio-Path Holdings Awarded Grant From The U.S. Government's Qualifying Therapeutic Discovery Project Program |
| Aug 17, 2010 |
Bio-Path Holdings Reports Fiscal 2010 Second Quarter Financial Results
Company Also Completes Initial Sale of Registered Shares Under Financing With Lincoln Park Capital
|
| Jul 29, 2010 |
Bio-Path Holdings announces Dosing of First Patient in a Phase I Clinical Trial of its Liposomal Grb-2 Cancer Drug Candidate |
| Jun 4, 2010 |
Bio-Path Holdings Signs Equity Financing Deal
Equity Purchase Agreement With Institutional Investor Lincoln Park Capital to Provide Up to $7 Million In New Capital
|
| Mar 12, 2010 |
FDA Allows IND For Bio-Path Holdings' Liposomal Grb-2
Company to Commence Phase I Clinical Trial Of Its Cancer Drug To Treat CML, AML, ALL, & MDS |
| Dec 14, 2009 |
Bio-Path Holdings, Inc. Completes Private Placement Capital Raise and Provides Update to IND Status |
| Nov 2, 2009 |
Bio-Path Holdings, Inc. Operations Update
|
| Sep 22, 2009 |
Bio-Path Holdings, Inc. Announces Plans To Develop
Liposome Tumor Targeting Technology Licensed from The
University of Texas M. D. Anderson Cancer Center
|
| Jun 23, 2009 |
Bio-Path Holdings, Inc. Provides Operations Update and Overview Of New Targeting Technology
|
| Jun 6, 2009 |
Proxy Statement and Proxy |
| Apr 14, 2009 |
Bio-Path Holdings, Inc. Announces Clinical Support Agreement With ACORN And Names Bradley G. Somer, M.D., As Medical Officer For Phase I Clinical Trial |
| Dec 10, 2008 |
Letter To Shareholders |
| Dec 3, 2008 |
Bio-Path Holdings, Inc. Retains Alliance Advisors, LLC to Implement Investor Relations Program |
| Nov 17, 2008 |
Bio-Path Holdings, Inc. Announces the Signing of a Drug Manufacturing Agreement with Althea Technologies, Inc. |
| Jun 23, 2008 |
Bio-Path Holdings Announces Dr. Hans A. de Hann Has Joined The Company As Medical Director |
| Mar 3, 2008 |
Bio-Path Becomes a Publicly Traded Company
|
